 He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and was instrumental in the rapid licensing of genetically engineered human insulin and human growth hormone.From 1985 to 1989, he was a special assistant to the FDA commissioner and from 1989 to 1993, the founding director of the FDA's Office of Biotechnology.Since joining the Hoover Institution in 1994, Miller authored books and articles in scholarly journals, newspapers and online.